Y U So Mad?

Clay Siegall Discusses About The Success Of Seattle Genetics

May
15

Clay Siegall is the founder and CEO of a renowned biotech company, Seattle Genetics. Recently, he discussed about his journey with the company. When he was growing up, he developed a keen interest in the field of medicine. He was also thrilled by the power of technology. While studying zoology at the University of Maryland, he experienced the pain of seeing his father struggle with cancer. This situation fueled his desire to explore other options of developing cancer treatment. To this end, he founded Seattle genetics through which he focuses on the development of cancer therapies that protect normal cells from damage. Clay Siegall attributes the company’s success to the sales professionals who have extensive experience in the biotech technology and are highly knowledgeable about the company’s products. He said that success comes with an undying passion to work intensely.

In addition, Dr. Clay Siegall serves as Seattle Genetics’ president. He studied genetics at the George Washington University where he earned his PhD. He applies his vast knowledge in genetics and combines it with vigorous research and scientific innovation to come up with the most appropriate cancer therapies. Seattle Genetics pioneered the development of antibody-drug conjugates (ADCs), with its first drug, ADCETRIS, being approved by the FDA. The company collaborates with Takeda Pharmaceutical Company to sell ADCETRIS to more than 65 countries. The company also partners with other biotech companies in the production and licensing of technologies used in the development of ADCETRIS.

Siegall has worked hard to ensure that the corporation has adequate funds to run its operations. The executive has secured over $1.2 billion from public and private sources, including the company’s initial public offering of 2001. He seeks to ensure that ADCETRIS is approved in more countries. Previously, he rendered his services for Bristol-Myers Squibb Pharmaceutical Research Institute. He has also worked for the National Cancer Institute as well as the National Institutes of Health. Presently, Siegall sits to the boards of Washington Roundtable, Alder BioPharmaceuticals and Ultragenyx Pharmaceutical. He is the recipient of the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. In 2012, Clay was presented with the Pacific Northwest Ernst & Young Entrepreneur of the Year. Over the years, he has authored over 70 publications. Notably, Clay holds 15 patents.